Loading
Andrew Wardley is a breast oncologist involved in the PERSEPHONE trial of shorter trastuzumab.
Andrew Wardley is a consultant medical oncologist at The Christie NHS Foundation Trust and Honorary Professor at the University of Manchester. He specialises in breast cancer, HER2-positive disease and adjuvant trials. He contributed to PERSEPHONE, the trial that compared six months with twelve months of adjuvant trastuzumab. His papers include the monarcHER phase 2 trial of abemaciclib plus trastuzumab with or without fulvestrant in hormone receptor-positive, HER2-positive advanced breast cancer, the PERUSE study of first-line pertuzumab with trastuzumab and a taxane, and a study of enzalutamide with trastuzumab in HER2-positive, androgen receptor-positive disease. His publications are listed on PubMed.
Shares PERSEPHONE, Trastuzumab, HER2-positive breast cancer.
Shares Breast cancer research and treatment, HER2-positive breast cancer.
Shares PERSEPHONE, Trastuzumab, HER2-positive breast cancer.
Shares PERSEPHONE, Trastuzumab, HER2-positive breast cancer.
Shares Trastuzumab, HER2-positive breast cancer.
Shares Trastuzumab, HER2-positive breast cancer.
Shares Trastuzumab, HER2-positive breast cancer.
Shares Trastuzumab, HER2-positive breast cancer.